ClinicalTrials.gg
CompletedNCT00728351Updated Dec 19, 2020

Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)

A Phase 3 interventional study of vildagliptin + metformin and metformin in Diabetes Mellitus, Type 2, sponsored by Novartis Pharmaceuticals. Completed at 63 sites in 5 countries. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2020-12-19.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
317
Allocation
Randomized
Ages
18 Years to 78 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 119 studies testing vildagliptin in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Vildagliptin · Diabetes Mellitus, Type 2.

Enrollment
36th of 118
317 · median 162
Started
2008
with 6 others
Phase 3
63 of 119
none open now
Registered
52nd of 119
by date
Lead sponsor
47 of 119
Novartis Pharmaceuticals

Among the 119 studies testing vildagliptin in Diabetes Mellitus, Type 2, this one is the 36th largest by enrollment of the 118 interventional ones that give a count, is one of 7 that started in 2008, is one of 63 in phase 3, and was the 52nd registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 119 studies testing vildagliptin in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About vildagliptin

Vildagliptin: first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 78 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 119 studies testing vildagliptin in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The present study is designed to evaluate the efficacy and safety of fixed combination therapy of vildagliptin and metformin (25/1000 mg bid) in patients with type 2 diabetes inadequately controlled with prior metformin monotherapy.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Type 2 diabetes, vildagliptin
04

Who can participate

Ages eligible
18 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of T2DM treated with Metformin

Exclusion criteria

Exclusion Criteria:

  • FPG >= 260 mg/dL (14.4mmol/L)

Other protocol-defined inclusion/exclusion criteria may apply

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
317 participants (actual)

Study arms

  • Experimental
    vildagliptin + metformin

    Drug: vildagliptin + metformin

  • Active comparator
    metformin

    Drug: metformin

Interventions

06

What researchers measure

Primary outcomes

  1. HbA1c reduction after 24 weeks of treatment in patients with T2DM inadequately controlled with metformin monotherapy

    Time frame: 24 weeks

Secondary outcomes

  1. FPG reduction

    Time frame: 24 weeks

  2. Safety and tolerability

    Time frame: 24 weeks

  3. Body weight change from baseline

    Time frame: 24 weeks

  4. Changes in the fasting lipid profile

    Time frame: 24 weeks

07

Study locations

63 sites
  • Pine Bluff, Arkansas 71603, United States
  • Long Beach, California 90806, United States
  • Denver, Colorado 80209, United States
  • Bangor, Maine 04401, United States
  • Billings, Montana 59102, United States
  • Novartis Investigative Site
    New Brunswick, New Jersey 08903, United States
  • Trenton, New Jersey 08611, United States
  • Wilmington, North Carolina 28409, United States
  • Oklahoma City, Oklahoma 73104, United States
  • Uniontown, Pennsylvania, United States
  • Taylors, South Carolina 29687, United States
  • Houston, Texas 77023, United States
  • Houston, Texas 77074, United States
  • Houston, Texas 77081, United States
  • Norfolk, Virginia 23510, United States
  • Wenatchee, Washington 98801, United States
  • Cabinet d'Endocrinologie-Maladies Métaboliques
    Annecy, 74000, France
  • Service Endocrinologic & Metabolisme
    Paris, 75013, France
  • Polycliniques des minguettes
    Venissieux, 69200, France
  • Hausärztliche Praxis
    Aschaffenburg, 63739, Germany
  • Klinische Forschung Berlin Mitte GmbH
    Berlin, 10117, Germany
  • AVK
    Berlin, 12157, Germany
  • Gemeinschaftspraxis
    Celle, 29221, Germany
  • Malteser KM
    Duisburg, 42259, Germany
  • Untertrintroper Hausarztzentrum
    Essen, 45359, Germany
  • Gefrees, 95482, Germany
  • Diabeteszentrum Billstedt/Horn
    Hamburg, 22119, Germany
  • Diabetologische Schwerpunktpraxis
    Hamburg, 22119, Germany
  • St. Elisabeth Krankenhaus Leipzig
    Leipzig, 04229, Germany
  • Diabetes-Schwerpunktpraxis Studienambulanz
    Leipzig, 04257, Germany
  • Institut für Diabetes-forschung Münster
    Münster, 48145, Germany
  • Praxis Dr. Alawi
    Saarlouis, 66740, Germany
  • DDT
    Siegen, 57072, Germany
  • Diabetologische Schwerpunktpraxis
    Sinsheim, 74889, Germany
  • Praxis
    Wangen, 88239, Germany
  • Synexus Magyarorszag
    Budapest, 1036, Hungary
  • Uzsoki Hospital
    Budapest, 1145, Hungary
  • Budapest, Hungary
  • Europ-Med Orvosi Szolgaltato Kft
    Budaörs, 2040, Hungary
  • Kenezy Hospital
    Debrecen, Hungary
  • Gyngyosi Korhaz Kft
    Gyongyos, 3200, Hungary
  • Petz Aladar County
    Györ, 9024, Hungary
  • Selye Janos Korhaz es Rendelointezet
    Komarom, 2900, Hungary
  • DIAPED Kft., MRC
    Meggyesalja U., 122, Hungary
  • Josa Andras Teaching Hospital
    Nyiregyhaza, 4400, Hungary
  • Vas Megyei Markuscvszky Lajos Korhaz
    Szombathely, 9700, Hungary
  • Zala County Hospital
    Zalaegerszeg, Hungary
  • NZOZ Specjalistyczny Ośrodek Internistyczno - Diabetologiczny Białystok
    Bialystok, 15-435, Poland
  • Gdanska Poradnia Cukrzycowa
    Gdansk, 80-858, Poland
  • Gabinet Kardiologiczny Mediplus
    Gdynia, 81-423, Poland
  • NZOZ "Esculap" S.C.
    Gniewkowo, 88-140, Poland
  • SZPZOZ Szpital Zachodni im. Jana Pawla II
    Grodzisk Mazowiecki, 05-825, Poland
  • NZOZ Terapia Optima
    Katowice, 40-752, Poland
  • Poradnia Diabetologiczna, Zespol Opieki Zdrowotnej w Leczycy
    Leczyca, 99-100, Poland
  • Zespół Opieki Zdrowotnej w Łęczycy, Poradnia Diabetologiczna Łeczyca
    Leczyca, 99-100, Poland
  • Instytut Cantrum Zdrowia Matki Polki
    Lodz, 93-338, Poland
  • NZOZ Special-Med
    Lublin, 20-044, Poland
  • Szspital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Ponza
    Poznan, 60-569, Poland
  • Lecznica Prosen-SMO NZOZ
    Warszawa, 01-231, Poland
  • Centrum Leczenia Chorob Cywilizacyjnych
    Warszawa, 02-777, Poland
  • NZCZ Regionalna Poradnia Diabetologiczna
    Wroclaw, 50-127, Poland
  • Samodzielny Publiczny Szpital Kliniczny Nr 1
    Wroclaw, 50-367, Poland
  • Samodzielny Publiczny Szpital Kliniczny NR 1 im. Prof. Stanislawa Szysko SAM
    Zabrze, 41-800, Poland
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008 and a primary completion of Feb 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2008
First posted
Aug 5, 2008
Start
Jun 2008
Primary completionActual
Feb 2010
Results delay requested
Jan 2, 2013
Last update
Dec 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00728351
Responsible party
Sponsor
First posted
Aug 5, 2008
Start date
Jun 2008
Primary completion
Feb 2010
Last update
Dec 19, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vildagliptin · Metformin

Start the discussion